Table 1.
Characteristics of the study group (2000–2010).
| Characteristics | Value | |||||
|---|---|---|---|---|---|---|
| CR1 | CR2 | Total (n/%) | ||||
| MRD+ (n/%) | MRD− (n/%) | MRD+ (n/%) | MRD− (n/%) | |||
| Patients (number, %) | 10 (100%) | 19 (100%) | 9 (100%) | 21 (100%) | 59 (100%) | |
| Sex | ||||||
| Male | 4 (40%) | 6 (31.6%) | 5 (55.5%) | 13 (90.5%) | 28 (47.5%) | |
| Female | 6 (60%) | 13 (68.4%) | 4 (44.4%) | 8 (38.1%) | 31 (52.5%) | |
| Age | ||||||
| Range | 28–62 | 20–61 | 29–65 | 30–65 | 20–65 | |
| Median | 51 | 44 | 48 | 43 | 48 | |
| Mean | 51.0 | 42.4 | 49.0 | 46.3 | 46.3 | |
| Initial cytogenetics | ||||||
| Favorable | / | / | / | 1 (4.8%) | 1 (1.7%) | |
| Intermediate | 4 (40%) | 7 (36.8%) | 5 (55.5%) | 17 (81%) | 33 (55.9%) | |
| Unfavorable | 6 (60%) | 10 (52.6%) | 2 (22.2%) | 1 (4.8%) | 19 (32.2%) | |
| Unknown | / | 2 (10.5%) | 2 (22.2%) | 2 (9.5%) | 6 (10.2%) | |
| Diagnosis | ||||||
| AML de novo | 4 (40%) | 13 (68.4%) | 7 (77.7%) | 17 (81%) | 41 (69.5%) | |
| Secondary AML | 6 (60%) | 6 (31.6%) | 2 (22.2%) | 4 (19%) | 18 (30.5%) | |
| Previous Stem Cell Transplant | 8 (13.6%) | |||||
| Autologous | / | / | 3 (33.3%) | 4 (19%) | 7 (11.9%) | |
| Allogeneic | / | / | / | 1 (4.8%) | 1 (1.7%) | |
| Disease status at transplantation | ||||||
| CR1 | 10 (100%) | 19 (100%) | / | / | 29 (49.1%) | |
| CR2 | / | / | 9 (100%) | 21 (100%) | 30 (50.8%) | |
| ECOG status | ||||||
| 0 | 3 (30%) | 10 (52.6%) | 1 (11.1%) | 4 (19%) | 18 (30.5%) | |
| 1 | 1 (10%) | 2 (10.5%) | 3 (33.3%) | 3 (14.3%) | 9 (15.2%) | |
| 2 | 1 (10%) | / | 1 (11.1%) | 3 (14.3%) | 5 (%) | |
| 3–4 | / | 1 (5.3%) | 1 (11.1%) | / | 2 (%) | |
| unknown | 5 (50%) | 6 (31.6%) | 3 (33.3%) | 11 (52.4%) | 25 (%) | |
| MRD defined by | ||||||
| Flow cytometry | 3 (30%) | / | 6 (66.6%) | / | 9 (15.2%) | |
| Cytogenetics | 4 (40%) | / | 4 (44.4%) | / | 8 (13.6%) | |
| FISH | 5 (50%) | / | 2 (22.2%) | / | 7 (11.9%) | |
| Leukemia cutis | / | / | 1 (11.1%) | / | 1 (1.7%) | |
| Type of transplant | ||||||
| Related | 6 (60%) | 10 (52.6%) | 6 (66.6%) | 12 (57.1%) | 34 (57.6%) | |
| Unrelated | 4 (40%) | 9 (47.4%) | 3 (33.3%) | 9 (42.9%) | 25 (42.4%) | |
| Graft type | ||||||
| PBSC | 6 (60%) | 11 (57.9%) | 4 (44.4%) | 16 (76.2%) | 37 (62.7%) | |
| Bone marrow | 1 (20%) | 3 (15.8%) | 3 (33.3%) | 3 (14.3%) | 10 (16.9%) | |
| Cord blood | 3 (30%) | 5 (26.3%) | 2 (22.2%) | 2 (9.5%) | 12 (20.3%) | |
| Donor-recipient HLA match | ||||||
| Matched (8/8, 6/6) | 7 (70%) | 14 (73.7%) | 7 (77.7%) | 18 (85.7%) | 46 (78%) | |
| Mismatched (7/8, 5/6) | 2 (20%) | 1 (5.3%) | 2 (22.2%) | 2 (9.5%) | 7 (11.9%) | |
| Mismatched (4/6) | 1 (10%) | 4 (21%) | / | 1 (4.8%) | 6 (10.2%) | |
| Condition intensity | ||||||
| Myeloablative | 9 (90%) | 19 (100%) | 7 (77.7%) | 17 (81%) | 52 (88.2%) | |
| Reduced intensity | 1 (10%) | / | 2 (22.2%) | 4 (19%) | 7 (11.9%) | |
| Conditioning protocol | ||||||
| Non TBI | 5 (50%) | 11 (57.9%) | 4 (44.4%) | 12 (57.2%) | 32 (54.3%) | |
| TBI | 5 (50%) | 8 (42.1%) | 5 (55.5%) | 9 (42.9%) | 27 (45.7%) | |
| Relapse | ||||||
| Yes | 5 (50%) | 2 (10.5%) | 6 (66.6%) | 4 (19%) | 17 (28.8%) | |
| No | 5 (50%) | 17 (89.5%) | 3 (33.3%) | 17 (81%) | 42 (71.2%) | |
| Present status | ||||||
| Alive | 2 (20%) | 12 (63.2%) | 2 (22.2%) | 11 (52.4%) | 27 (45.7%) | |
| Diseased | 8 (80%) | 7 (36.8%) | 7 (77.7%) | 10 (47.6%) | 32 (54.3%) | |
MRD: minimal residual disease; MRD+: patients with MRD; MRD−: patients without MRD; CR1: first complete remission; CR2: second complete remission; M: male; F: female; AML: acute myeloid leukemia; ECOG: Eastern Cooperative Oncology Group; FISH: fluorescence in situ hybridization; PBSC: peripheral blood stem cell; TBI: total body irradiation.